Literature DB >> 26822830

Huntington disease: Boosting PPARδ blocks neurodegeneration.

Sarah Crunkhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26822830     DOI： 10.1038/nrd.2016.1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.

Authors:  Audrey S Dickey; Victor V Pineda; Taiji Tsunemi; Patrick P Liu; Helen C Miranda; Stephen K Gilmore-Hall; Nicole Lomas; Kunal R Sampat; Anne Buttgereit; Mark-Joseph Manalang Torres; April L Flores; Martin Arreola; Nicolas Arbez; Sergey S Akimov; Terry Gaasterland; Eduardo R Lazarowski; Christopher A Ross; Gene W Yeo; Bryce L Sopher; Gavin K Magnuson; Anthony B Pinkerton; Eliezer Masliah; Albert R La Spada
Journal:  Nat Med       Date:  2015-12-07       Impact factor: 53.440
  1 in total
  3 in total

Review 1.  Combination of RNA Interference and Stem Cells for Treatment of Central Nervous System Diseases.

Authors:  Xue-Qin Hou; Lei Wang; Fu-Gang Wang; Xiao-Min Zhao; Han-Ting Zhang
Journal:  Genes (Basel)       Date:  2017-05-06       Impact factor: 4.096

2.  HBXIP activates the PPARδ/NF-κB feedback loop resulting in cell proliferation.

Authors:  Qian Liu; Wenbin Lu; Chunxia Yang; Yue Wang; Wenjing Li; Ying Chu; Jianzhong Deng; Yongzhong Hou; Jianhua Jin
Journal:  Oncotarget       Date:  2017-12-08

Review 3.  Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders.

Authors:  Gerwyn Morris; Michael Maes; Michael Berk; André F Carvalho; Basant K Puri
Journal:  Eur Psychiatry       Date:  2020-01-31       Impact factor: 5.361
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.